ResearchMoz presents professional and in-depth study of "Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers".
The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as inflammation, the scarring of lung tissue and excessive production of mucus in the airways. This report focuses on the key therapy area indications of asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF).
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1339595
The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.
The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the underlying cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. However, over the past decade the treatment of respiratory disorders has developed significantly, with novel and targeted therapies emerging onto the market. The approval of the products Kalydeco and Orkambi, in 2012 and 2014 respectively, gave patients disease-modifying treatment options for CF. Targeted biologics have also emerged such as omalizumab and Nucala for the treatment of asthma.
Overall, 937 products are being actively developed in the respiratory pipeline. The pipelines of asthma, COPD, IPF and CF contain 261, 106, 79 and 131 products, respectively. Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area.
Scope
Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%. What is driving this growth?
The leading companies in terms of market share are GSK, AstraZeneca and Boehringer Ingelheim. Which of these are forecast to experience the largest growth?
View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-respiratory-drugs-market-to-2023-a-changing-therapeutic-landscape-as-key-patents-expire-and-biologics-targeted-therapies-and-cftr-modulators-for-asthma-and-cystic-fibrosis-treatment-emerge-as-market-growth-drivers-report.html/toc
There have been many new approvals in the therapy area. Which drugs will achieve blockbuster status?
The market has been dominated by ICS/LABA therapies. What classes of drugs dominate the market and which will dominate over the forecast period?
There are 930 respiratory products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
Respiratory disorders clinical trials have an overall attrition rate of around 70%, what can companies do to maximize their chance of success?
Reasons to buy
Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
Analyze the respiratory pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at respiratory product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
Identify commercial opportunities in the respiratory deals landscape by analyzing trends in licensing and co-development deals.
Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 12
2.1 Therapy Area Introduction 12
2.2 Symptoms 13
2.3 Diagnosis 13
2.3.1 Asthma 13
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1339595
2.3.2 Chronic Obstructive Pulmonary Disease 14
2.3.3 Idiopathic Pulmonary Fibrosis 15
2.3.4 Cystic Fibrosis 16
2.4 Etiology and Pathophysiology 16
2.4.1 Asthma 16
2.4.2 Chronic Obstructive Pulmonary Disease 18
2.4.3 Idiopathic Pulmonary Fibrosis 20
2.4.4 Cystic Fibrosis 22
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as inflammation, the scarring of lung tissue and excessive production of mucus in the airways. This report focuses on the key therapy area indications of asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF).
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1339595
The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.
The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the underlying cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. However, over the past decade the treatment of respiratory disorders has developed significantly, with novel and targeted therapies emerging onto the market. The approval of the products Kalydeco and Orkambi, in 2012 and 2014 respectively, gave patients disease-modifying treatment options for CF. Targeted biologics have also emerged such as omalizumab and Nucala for the treatment of asthma.
Overall, 937 products are being actively developed in the respiratory pipeline. The pipelines of asthma, COPD, IPF and CF contain 261, 106, 79 and 131 products, respectively. Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area.
Scope
Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%. What is driving this growth?
The leading companies in terms of market share are GSK, AstraZeneca and Boehringer Ingelheim. Which of these are forecast to experience the largest growth?
View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-respiratory-drugs-market-to-2023-a-changing-therapeutic-landscape-as-key-patents-expire-and-biologics-targeted-therapies-and-cftr-modulators-for-asthma-and-cystic-fibrosis-treatment-emerge-as-market-growth-drivers-report.html/toc
There have been many new approvals in the therapy area. Which drugs will achieve blockbuster status?
The market has been dominated by ICS/LABA therapies. What classes of drugs dominate the market and which will dominate over the forecast period?
There are 930 respiratory products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
Respiratory disorders clinical trials have an overall attrition rate of around 70%, what can companies do to maximize their chance of success?
Reasons to buy
Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
Analyze the respiratory pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at respiratory product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
Identify commercial opportunities in the respiratory deals landscape by analyzing trends in licensing and co-development deals.
Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 12
2.1 Therapy Area Introduction 12
2.2 Symptoms 13
2.3 Diagnosis 13
2.3.1 Asthma 13
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1339595
2.3.2 Chronic Obstructive Pulmonary Disease 14
2.3.3 Idiopathic Pulmonary Fibrosis 15
2.3.4 Cystic Fibrosis 16
2.4 Etiology and Pathophysiology 16
2.4.1 Asthma 16
2.4.2 Chronic Obstructive Pulmonary Disease 18
2.4.3 Idiopathic Pulmonary Fibrosis 20
2.4.4 Cystic Fibrosis 22
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
No comments:
Post a Comment